Excluded Drug Criteria. Coverage Duration. Age Restrictions. Prescriber Restrictions. Prior Authorization Type Description.

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "Excluded Drug Criteria. Coverage Duration. Age Restrictions. Prescriber Restrictions. Prior Authorization Type Description."

Transcription

1 2015 Cigna-HealthSpring - H Cigna-HealthSpring Preferred (HMO), Cigna-HealthSpring Achieve Plus (HMO SNP), Cigna- HealthSpring Preferred Plus (HMO) (Updated December 2015) Name Other ABELCET ABRAXANE ACETYLCYSTEINE ACTEMRA ACTEMRA Documentation of diagnosis and past medication history. Treatment of rheumatoid arthritis (RA) when ANY of the following criteria are met: 1) history of positive clinical response to tocilizumab therapy OR 2) inadequate response, intolerance, or contraindication to at least one disease-modifying anti-rheumatic drug (DMARD) (i.e., Methotrexate (MTX) Azathioprine, gold, Hydroxychloroquine, Penicillamine, Sulfasalazine). For RA new starts that meet the above criteria, the patient must also have failure, contraindication or intolerance to Enbrel or Humira before authorization of Actemra. BvsD Determinaton ACTHAR HP ACTHAR HP All FDA-approved excluded from part D. For the treatment of multiple sclerosis the patient must have failure, contraindication or intolerance to intravenous corticosteroid therapy and currently maintained on one of the following formulary drugs Avonex, Copaxone, Extavia or Rebif before Acthar HP is authorized. ACYCLOVIR SODIUM ADCIRCA ADCIRCA All FDA-approved excluded from part D. Medical documentation of pulmonary arterial hypertension. ALBUTEROL SULFATE ALIMTA ALORA HRM - Estrogens Safer alternatives to the estrogen high risk medications depend on the indication. For Hot Flashes, safer alternatives are: Estradiol Valerate, Depo-Estradiol, SSRIs, venlafaxine, gabapentin, and Femring. For Vaginal Symptoms, safer alternatives are: Premarin Cream, Estring, Femring, and Estradiol Valerate. For Bone Density, safer alternatives are: alendronate, risedronate, Evista, and Prolia. ALOSETRON LOTRONEX Lotronex (alosetron) will not be approved for use in men, as safety and efficacy in men has not been established. must be enrolled in the prescribing program for alosetron.

2 Name Other ALOXI AMBISOME AMIFOSTINE AMINOSYN AMINOSYN 7%/ELECTROLYTES AMINOSYN 8.5%/ELECTROLYTES AMINOSYN II AMINOSYN II 8.5%/ELECTROLYTES AMINOSYN M AMINOSYN-HBC AMINOSYN-PF AMINOSYN-PF 5.2 % AMINOSYN-PF 7% AMITRIPTYLINE HCL to New Starts HRM - Tricyclic Antidepressants Safer alternatives depend on indication. For Depression, safer alternatives are: Nortriptyline, Protriptyline, Desipramine, Amoxapine, Citalopram, Venlafaxine, Fluoxetine, Paroxetine, Sertraline, Duloxetine, and Bupropion. For headache prophylaxis, safer alternatives are: Propranolol, Topiramate, and Divalproex sodium. For headache treatment, safer alternatives are: Sumatriptan, Naratriptan, and Dihydroergotamine. For Pain/Neuropathy, safer alternatives are: Duloxetine, Lyrica, and Gabapentin. AMPHOTERICIN B

3 Name Other AMPYRA AMPYRA Documentation of diagnosis. Ampyra is considered medically necessary for patients with multiple sclerosis with medical documentation of impaired walking ability. ANGELIQ HRM - Estrogens Safer alternatives to the estrogen high risk medications depend on the indication. For Hot Flashes, safer alternatives are: Estradiol Valerate, Depo-Estradiol, SSRIs, venlafaxine, gabapentin, and Femring. For Vaginal Symptoms, safer alternatives are: Premarin Cream, Estring, Femring, and Estradiol Valerate. For Bone Density, safer alternatives are: alendronate, risedronate, Evista, and Prolia. ANZEMET ANZEMET INJ ARALAST NP Alpha-1 Proteinase Inhibitor Therapy All FDA-approved excluded from part D. Intravenous alpha1-proteinase inhibitor (human) is authorized for the treatment of congenital alpha1-proteinase inhibitor deficiency-associated lung disease when all of the following criteria are met: 1) alpha1-antitrypsin (AAT) concentration less than 80mg/dl or less than 11 micromolar and 2) obstructive lung disease as defined by a forced expiratory volume in one second (FEV1) of 30 to 65% of predicted or a rapid decline in lung function defined as a change in FEV1 of greater than 120ml per year. BvsD Determination. ARANESP ALBUMIN FREE ARCALYST HEMATOPOIETICS ARCALYST For the indication of anemia, documentation of Hemoglobin less than 11, Hematocrit, transferrin saturation greater than 20%, and ferritin levels greater than 100 obtained over the last 3 months. Documentation of diagnosis of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS). 12 years of age and older 6 months BvD Determination. Patients must also have failure, contraindication or intolerance to Procrit or Aranesp before Epogen will be authorized. BvsD Determination ARRANON ARZERRA ASCOMP/CODEINE HRM - Butalbital Combinations Safer alternatives are: naproxen sodium and ibuprofen. ASTAGRAF XL AUBAGIO AUBAGIO Aubagio will be used as monotherapy for the treatment of multiple sclerosis. Patient must also have failure, contraindication or intolerance to one of the following formulary alternatives Avonex, Copaxone, Extavia or Rebif before Aubagio will be authorized. AVASTIN

4 Name AVONEX IMMUNOMODULATO RS Other AZACITIDINE AZATHIOPRINE BENLYSTA BENLYSTA The patient must have a positive autoantibody test (i.e., antinuclear antibody [ANA] greater than or equal to 1:80 and/or anti-double-stranded DNA [anti-dsdna] greater than or equal to 30 IU/ml) AND active disease state as documented by a SELENA-SLEDAI score of 6 or greater on the current treatment regimen. The patient must be receiving one standard therapy for SLE with any of the following: corticosteroids, hydroxychloroquine, immunosuppressives (cyclophosphamide, azathioprine, mycophenolate, methotrexate, cyclosporine) or nonsteroidal anti-inflammatory drugs AND there must be an absence of severe active lupus nephritis or severe active central nervous system lupus before Benlysta is authorized. BvsD Determination BENZTROPINE MESYLATE HRM - Benztropine If only one (1) safer formulary alternative is available, then only that particular medication would need to be documented as tried and failed or clinical rationale provided as to why that one safer formulary alternative is not Safer alternatives depend on indication. For Parkinsonism, safer alternatives are: Carbidopa/Levodopa, Pramipexole, Ropinirole, Bromocriptine, Amantadine, and Selegiline. For extrapyramidal symptoms, a safer alternative is: Amantadine. BERINERT BERINERT Berinert is authorized for the treatment of acute angioedema attacks with hereditary angioedema (HAE) when BOTH of the following criteria are met: 1) confirmed diagnosis of (HAE) as evidenced by a C4 level below the lower limit of normal as defined by the laboratory performing the test AND EITHER a) C1 inhibitor (C1INH) antigenic level below the lower limit 10 years and older of normal as defined by the laboratory performing the test or b) C1INH functional level below the lower limit of normal as defined by the laboratory performing the test AND 2) history of a moderate or severe attack (e.g., airway swelling, severe abdominal pain, facial swelling, nausea and vomiting, painful facial distortion). BETHKIS BICNU BIVIGAM BLEOMYCIN SULFATE BONIVA

5 Name BOTOX BOTOX Exclude when used for cosmetic purposes. Documentation of diagnosis 3 months Other BROVANA BUDESONIDE BUSULFEX BUTAL/ASA/CAFF HRM - Butalbital Combinations Safer alternatives are: naproxen sodium and ibuprofen. BUTALBITAL/ACETA MINOPHEN HRM - Butalbital Combinations Safer alternatives are: naproxen sodium and ibuprofen. BUTALBITAL/ACETA MINOPHEN/CAFFEINE HRM - Butalbital Combinations Safer alternatives are: naproxen sodium and ibuprofen. BUTALBITAL/ACETA MINOPHEN/CAFFEINE /CODEINE HRM - Butalbital Combinations Safer alternatives are: naproxen sodium and ibuprofen.

6 Name Other BUTALBITAL/APAP/C AFFEINE HRM - Butalbital Combinations Safer alternatives are: naproxen sodium and ibuprofen. CALCITRIOL CARBOPLATIN CARIMUNE NANOFILTERED CARISOPRODOL HRM - Skeletal Muscle Relaxants documented the ongoing monitoring plan for the agent. age.prior Auth CARISOPRODOL/ASPI RIN HRM - Skeletal Muscle Relaxants documented the ongoing monitoring plan for the agent. age.prior Auth CARISOPRODOL/ASPI RIN/CODEINE HRM - Skeletal Muscle Relaxants documented the ongoing monitoring plan for the agent. age.prior Auth CELLCEPT CELLCEPT INTRAVENOUS CEREZYME

7 Name Other CESAMET CHLORDIAZEPOXIDE/ AMITRIPTYLINE to New Starts HRM - Tricyclic Antidepressants Safer alternatives depend on indication. For Depression, safer alternatives are: Nortriptyline, Protriptyline, Desipramine, Amoxapine, Citalopram, Venlafaxine, Fluoxetine, Paroxetine, Sertraline, Duloxetine, and Bupropion. For headache prophylaxis, safer alternatives are: Propranolol, Topiramate, and Divalproex sodium. For headache treatment, safer alternatives are: Sumatriptan, Naratriptan, and Dihydroergotamine. For Pain/Neuropathy, safer alternatives are: Duloxetine, Lyrica, and Gabapentin. CHLORZOXAZONE to New Starts HRM - Skeletal Muscle Relaxants documented the ongoing monitoring plan for the agent. CIALIS CIALIS All FDA-approved excluded from part D. Cialis 2.5mg and 5mg are only covered for the treatment of benign prostatic hyperplasia (BPH). CINRYZE CINRYZE Patient must have a confirmed diagnosis of HAE as evidenced by a C4 level below the lower limit of normal as defined by the laboratory performing the test AND EITHER of the following: 1) C1 inhibitor (C1INH) antigenic level below the lower limit of normal as defined by the laboratory performing the test 2) C1INH functional level below the lower limit of normal as defined by the laboratory performing the test or 3) known HAE-causing C1INH mutation. The patient must have a history of more than one severe event per month and have failure, contraindication or intolerance to one conventional therapy for HAE prophylaxis such as aminocaproic acid, danazol or tranexamic acid. CISPLATIN CLADRIBINE CLIMARA PRO HRM - Estrogens Safer alternatives to the estrogen high risk medications depend on the indication. For Hot Flashes, safer alternatives are: Estradiol Valerate, Depo-Estradiol, SSRIs, venlafaxine, gabapentin, and Femring. For Vaginal Symptoms, safer alternatives are: Premarin Cream, Estring, Femring, and Estradiol Valerate. For Bone Density, safer alternatives are: alendronate, risedronate, Evista, and Prolia. CLINIMIX 2.75%/DEXTROSE 5% CLINIMIX 4.25%/DEXTROSE 10%

8 Name Other CLINIMIX 4.25%/DEXTROSE 20% CLINIMIX 4.25%/DEXTROSE 25% CLINIMIX 4.25%/DEXTROSE 5% CLINIMIX 5%/DEXTROSE 15% CLINIMIX 5%/DEXTROSE 20% CLINIMIX 5%/DEXTROSE 25% CLINIMIX E 2.75%/DEXTROSE 10% CLINIMIX E 2.75%/DEXTROSE 5% CLINIMIX E 4.25%/DEXTROSE 25% CLINIMIX E 4.25%/DEXTROSE 5% CLINIMIX E 5%/DEXTROSE 15% CLINIMIX E 5%/DEXTROSE 20% CLINIMIX E 5%/DEXTROSE 25% CLINISOL SF 15% CLOLAR CLOMIPRAMINE HCL to New Starts HRM - Tricyclic Antidepressants Safer alternatives depend on indication. For Depression, safer alternatives are: Nortriptyline, Protriptyline, Desipramine, Amoxapine, Citalopram, Venlafaxine, Fluoxetine, Paroxetine, Sertraline, Duloxetine, and Bupropion. For headache prophylaxis, safer alternatives are: Propranolol, Topiramate, and Divalproex sodium. For headache treatment, safer alternatives are: Sumatriptan, Naratriptan, and Dihydroergotamine. For Pain/Neuropathy, safer alternatives are: Duloxetine, Lyrica, and Gabapentin.

9 Name Other COMBIPATCH HRM - Estrogens Safer alternatives to the estrogen high risk medications depend on the indication. For Hot Flashes, safer alternatives are: Estradiol Valerate, Depo-Estradiol, SSRIs, venlafaxine, gabapentin, and Femring. For Vaginal Symptoms, safer alternatives are: Premarin Cream, Estring, Femring, and Estradiol Valerate. For Bone Density, safer alternatives are: alendronate, risedronate, Evista, and Prolia. COSMEGEN CROMOLYN SODIUM CYCLOBENZAPRINE HCL HRM - Skeletal Muscle Relaxants documented the ongoing monitoring plan for the agent. CYCLOPHOSPHAMIDE CYCLOSPORINE CYCLOSPORINE MODIFIED CYPROHEPTADINE HCL HRM - Cyproheptadine failed one (1) safer formulary alternative if available or provided clinical rationale why the safer formulary alternative is not age.prior Auth For perennial and seasonal allergic rhinitis, safer alternatives are: Levocetirizine, Desloratadine. For any other indications, trial of formulary alternatives are not required. CYTARABINE CYTARABINE AQUEOUS DACARBAZINE DACTINOMYCIN

10 Name Other DAUNORUBICIN HCL DAUNOXOME DECITABINE DEXRAZOXANE DEXTROSE 10%/NACL 0.45% DEXTROSE 5% /ELECTROLYTE #48 VIAFLEX DEXTROSE 10% FLEX CONTAINER DEXTROSE 10%/NACL 0.2% DEXTROSE 2.5%/SODIUM CHLORIDE 0.45% DEXTROSE 5% DEXTROSE 20% DEXTROSE 25% DEXTROSE 30% DEXTROSE 30% PARTIAL FILL DEXTROSE 40% DEXTROSE 50% DEXTROSE 70% DEXTROSE 5%/NACL 0.2%

11 Name Other DEXTROSE 5%/NACL 0.225% DEXTROSE 5%/NACL 0.3% DEXTROSE 5%/NACL 0.33% DEXTROSE 5%/NACL 0.45% DEXTROSE 5%/NACL 0.9% DEXTROSE 5%/POTASSIUM CHLORIDE 0.15% DIFICID DIFICID 18 years of age and older. 10 days DIGOX HRM - Digoxin the physician has documented that the patient has tried digoxin 0.125mg daily or provided clinical rationale as to why the lower dose is not DIGOXIN HRM - Digoxin the physician has documented that the patient has tried digoxin 0.125mg daily or provided clinical rationale as to why the lower dose is not DIPYRIDAMOLE HRM - Platelet Modifying nts Safer alternatives are: Clopidogrel, Warfarin, Jantoven, and Aggrenox. DOCEFREZ DOCETAXEL

12 Name Other DOXEPIN HCL to New Starts HRM - Tricyclic Antidepressants Safer alternatives depend on indication. For Depression, safer alternatives are: Nortriptyline, Protriptyline, Desipramine, Amoxapine, Citalopram, Venlafaxine, Fluoxetine, Paroxetine, Sertraline, Duloxetine, and Bupropion. For headache prophylaxis, safer alternatives are: Propranolol, Topiramate, and Divalproex sodium. For headache treatment, safer alternatives are: Sumatriptan, Naratriptan, and Dihydroergotamine. For Pain/Neuropathy, safer alternatives are: Duloxetine, Lyrica, and Gabapentin. DOXERCALCIFEROL DOXORUBICIN HCL DOXORUBICIN HCL LIPOSOME DRONABINOL DYSPORT DYSPORT Exclude when used for cosmetic purposes. 3 months EGRIFTA EGRIFTA All FDA-approved excluded from part D. Males must have a waist circumference of at least 95cm (37.5in) and a waist-to-hip ratio of at least Females must have a waist circumference of at least 94cm (37in) and a waist-to-hip ratio of at least Patients must have a baseline CT documenting increased visceral adipose tissue (VAT). Reauthorization is contingent upon ONE of the following: 1) decrease in VAT measured by CT scan or 2) reduction of waist circumference and waist-to-hip ratio from baseline measurement. Patient must be on a stable antiretroviral regimen for at least 8 weeks. ELIGARD to New Starts ELIGARD Patient must have failure, contraindication or intolerance to Trelstar before Eligard is authorized. BvsD Determination ELITEK ELLENCE ELOXATIN EMEND

13 Name Other Use of Humira, Enbrel, or Remicade is considered medically necessary for the treatment of: 1. Rheumatoid Arthritis in patients that have tried and failed methotrexate OR at least 2 alternative disease modifying antirheumatic drugs (DMARDs). 2. Juvenile Rheumatoid Arthritis in patients that have tried and failed at least 2 DMARDs. 3. Ankylosing Spondylitis in patients that have tried and failed at least 1 non-steroidal antiinflammatory drug (NSAID), corticosteroid, OR sulfasalazine. 4. Plaque Psoriasis in patients that have: a) moderate to severe chronic disease, b) minimum body surface area (BSA) ENBREL IMMUNE SUPPRESSANTS Documentation of diagnosis and past medication history. involvement of greater than or equal to 5% OR involvement of the palms, soles, head, neck or genitalia, c) tried and failed at least 1 topical agent (topical steroid, calcipotriene, or tazarotene), AND d) tried and failed at least 1 systemic therapy (cyclosporine, methotrexate, or acitretin) OR phototherapy. 5. Psoriatic Arthritis in patients with active disease. In addition, use of Humira or Remicade is considered medically necessary for the treatment of: 1. Moderate to severe Crohn s Disease in patients that have tried and failed at least 2 of the following: immunomodulators, corticosteroids, or aminosalicylates. 2. Treatment of moderately to severely active ulcerative colitis in patients who have had inadequate response to at least 2 of the following: corticosteroids, sulfasalazine, mesalamine, azathioprine, 6-mercaptopurine. Use of Remicade will also be considered medically necessary for the treatment of fistulizing Crohn's disease. B vs D determination required for Remicade. Use of Humira, Enbrel, or Remicade is considered medically necessary for the treatment of: 1. Rheumatoid Arthritis in patients that have tried and failed methotrexate OR at least 2 alternative disease modifying antirheumatic drugs (DMARDs). 2. Juvenile Rheumatoid Arthritis in patients that have tried and failed at least 2 DMARDs. 3. Ankylosing Spondylitis in patients that have tried and failed at least 1 non-steroidal antiinflammatory drug (NSAID), corticosteroid, OR sulfasalazine. 4. Plaque Psoriasis in patients that have: a) moderate to severe chronic disease, b) minimum body surface area (BSA) ENBREL SURECLICK IMMUNE SUPPRESSANTS Documentation of diagnosis and past medication history. involvement of greater than or equal to 5% OR involvement of the palms, soles, head, neck or genitalia, c) tried and failed at least 1 topical agent (topical steroid, calcipotriene, or tazarotene), AND d) tried and failed at least 1 systemic therapy (cyclosporine, methotrexate, or acitretin) OR phototherapy. 5. Psoriatic Arthritis in patients with active disease. In addition, use of Humira or Remicade is considered medically necessary for the treatment of: 1. Moderate to severe Crohn s Disease in patients that have tried and failed at least 2 of the following: immunomodulators, corticosteroids, or aminosalicylates. 2. Treatment of moderately to severely active ulcerative colitis in patients who have had inadequate response to at least 2 of the following: corticosteroids, sulfasalazine, mesalamine, azathioprine, 6-mercaptopurine. Use of Remicade will also be considered medically necessary for the treatment of fistulizing Crohn's disease. B vs D determination required for Remicade. ENGERIX-B EPIRUBICIN HCL EPOGEN HEMATOPOIETICS For the indication of anemia, documentation of Hemoglobin less than 11, Hematocrit, transferrin saturation greater than 20%, and ferritin levels greater than 100 obtained over the last 3 months. 6 months BvD Determination. Patients must also have failure, contraindication or intolerance to Procrit or Aranesp before Epogen will be authorized. ERBITUX

14 Name Other ERGOLOID MESYLATES HRM - Antidementia nts Safer alternatives are: donepezil, galantamine and rivastigmine. ERWINAZE ESTRADIOL HRM - Estrogens Safer alternatives to the estrogen high risk medications depend on the indication. For Hot Flashes, safer alternatives are: Estradiol Valerate, Depo-Estradiol, SSRIs, venlafaxine, gabapentin, and Femring. For Vaginal Symptoms, safer alternatives are: Premarin Cream, Estring, Femring, and Estradiol Valerate. For Bone Density, safer alternatives are: alendronate, risedronate, Evista, and Prolia. ESTRADIOL/NORETHI NDRONE ACETATE HRM - Estrogens Safer alternatives to the estrogen high risk medications depend on the indication. For Hot Flashes, safer alternatives are: Estradiol Valerate, Depo-Estradiol, SSRIs, venlafaxine, gabapentin, and Femring. For Vaginal Symptoms, safer alternatives are: Premarin Cream, Estring, Femring, and Estradiol Valerate. For Bone Density, safer alternatives are: alendronate, risedronate, Evista, and Prolia. ESTROPIPATE HRM - Estrogens Safer alternatives to the estrogen high risk medications depend on the indication. For Hot Flashes, safer alternatives are: Estradiol Valerate, Depo-Estradiol, SSRIs, venlafaxine, gabapentin, and Femring. For Vaginal Symptoms, safer alternatives are: Premarin Cream, Estring, Femring, and Estradiol Valerate. For Bone Density, safer alternatives are: alendronate, risedronate, Evista, and Prolia. ETOPOPHOS ETOPOSIDE EXTAVIA IMMUNOMODULATO RS FABRAZYME FASLODEX

15 Name Other FEMHRT LOW DOSE HRM - Estrogens Safer alternatives to the estrogen high risk medications depend on the indication. For Hot Flashes, safer alternatives are: Estradiol Valerate, Depo-Estradiol, SSRIs, venlafaxine, gabapentin, and Femring. For Vaginal Symptoms, safer alternatives are: Premarin Cream, Estring, Femring, and Estradiol Valerate. For Bone Density, safer alternatives are: alendronate, risedronate, Evista, and Prolia. FENTANYL CITRATE FENTANYL CITRATE ORAL TRANSMUCOSAL TRANSMUCOSAL FENTANYL CITRATE All FDA-approved Documentation from the medical record of diagnosis. 16 years of age and older for fentanyl citrate (lozenge/troche). 18 years of age and older for Enrollment in the Transmucosal Immediate- Release Fentanyl (TIRF) REMS Access program. Transmucosal fentanyl products will only be covered with documentation of breakthrough cancer pain. The patient must be currently receiving and be tolerant to opioid therapy for persistent cancer pain.the patient must be enrolled in the TIRF REMS Access program. FIRAZYR FIRAZYR Patient must have a confirmed diagnosis of HAE as evidenced by a C4 level below the lower limit of normal as defined by the laboratory performing the test AND EITHER of the following: 1) C1 inhibitor (C1INH) antigenic level below the lower limit of normal as defined by the laboratory performing the test 2) C1INH functional level below the lower limit of normal as defined by the laboratory performing the test. Authorized for patients 18 years of age and older. The patient must have a history of a moderate or severe attack (e.g., airway swelling, severe abdominal pain, facial swelling, nausea and vomiting, painful facial distortion). FIRMAGON FLEBOGAMMA FLUDARABINE PHOSPHATE FLUOROURACIL FOLOTYN FOSCARNET SODIUM FREAMINE HBC 6.9% FREAMINE III GAMASTAN S/D GAMMAGARD LIQUID GAMMAGARD S/D

16 Name Other GAMMAGARD S/D IGA LESS THAN 1MCG/ML GAMMAKED GAMMAPLEX GAMUNEX-C GANCICLOVIR GATTEX GATTEX As long as the patient requires TPN, 3 months up to. GAZYVA GEMCITABINE GEMCITABINE HCL GENGRAF GENOTROPIN GENOTROPIN For GHD in children or adults, Turner Syndrome, SGA, SHOX gene deletion or growth delay in children with chronic kidney disease, the patient must have failure, contraindication or intolerance to Humatrope or Saizen before coverage of Genotropin. GENOTROPIN MINIQUICK GENOTROPIN For GHD in children or adults, Turner Syndrome, SGA, SHOX gene deletion or growth delay in children with chronic kidney disease, the patient must have failure, contraindication or intolerance to Humatrope or Saizen before coverage of Genotropin. GILENYA GILENYA Gilenya will be used as monotherapy for the treatment of multiple sclerosis. Patients must also have failure, contraindication or intolerance to one of the following formulary alternatives Avonex, Copaxone, Extavia or Rebif before Gilenya will be authorized. GLASSIA Alpha-1 Proteinase Inhibitor Therapy All FDA-approved excluded from part D. Intravenous alpha1-proteinase inhibitor (human) is authorized for the treatment of congenital alpha1-proteinase inhibitor deficiency-associated lung disease when all of the following criteria are met: 1) alpha1-antitrypsin (AAT) concentration less than 80mg/dl or less than 11 micromolar and 2) obstructive lung disease as defined by a forced expiratory volume in one second (FEV1) of 30 to 65% of predicted or a rapid decline in lung function defined as a change in FEV1 of greater than 120ml per year. BvsD Determination.

17 Name Other GLYBURIDE HRM - Glyburide failed glipizide or provided clinical rationale as to why that safer formulary alternative is not GLYBURIDE MICRONIZED HRM - Glyburide failed glipizide or provided clinical rationale as to why that safer formulary alternative is not GRANISETRON HCL GRANISOL HARVONI Prior authorization applies HARVONI Previous failure of Harvoni Genotype, HCV RNA viral levels prior to treatment, documentation of presence/absence of cirrhosis Hepatologist, gastroenterologist, infectious disease specialist or managed by a liver transplant center 12 to 24 weeks based on indication and established treatment guidelines HECORIA HEPATAMINE HEPATASOL HERCEPTIN HIZENTRA HUMATROPE HUMATROPE COMBO PACK HUMATROPE HUMATROPE

18 Name Other Use of Humira, Enbrel, or Remicade is considered medically necessary for the treatment of: 1. Rheumatoid Arthritis in patients that have tried and failed methotrexate OR at least 2 alternative disease modifying antirheumatic drugs (DMARDs). 2. Juvenile Rheumatoid Arthritis in patients that have tried and failed at least 2 DMARDs. 3. Ankylosing Spondylitis in patients that have tried and failed at least 1 non-steroidal antiinflammatory drug (NSAID), corticosteroid, OR sulfasalazine. 4. Plaque Psoriasis in patients that have: a) moderate to severe chronic disease, b) minimum body surface area (BSA) HUMIRA IMMUNE SUPPRESSANTS Documentation of diagnosis and past medication history. involvement of greater than or equal to 5% OR involvement of the palms, soles, head, neck or genitalia, c) tried and failed at least 1 topical agent (topical steroid, calcipotriene, or tazarotene), AND d) tried and failed at least 1 systemic therapy (cyclosporine, methotrexate, or acitretin) OR phototherapy. 5. Psoriatic Arthritis in patients with active disease. In addition, use of Humira or Remicade is considered medically necessary for the treatment of: 1. Moderate to severe Crohn s Disease in patients that have tried and failed at least 2 of the following: immunomodulators, corticosteroids, or aminosalicylates. 2. Treatment of moderately to severely active ulcerative colitis in patients who have had inadequate response to at least 2 of the following: corticosteroids, sulfasalazine, mesalamine, azathioprine, 6-mercaptopurine. Use of Remicade will also be considered medically necessary for the treatment of fistulizing Crohn's disease. B vs D determination required for Remicade. Use of Humira, Enbrel, or Remicade is considered medically necessary for the treatment of: 1. Rheumatoid Arthritis in patients that have tried and failed methotrexate OR at least 2 alternative disease modifying antirheumatic drugs (DMARDs). 2. Juvenile Rheumatoid Arthritis in patients that have tried and failed at least 2 DMARDs. 3. Ankylosing Spondylitis in patients that have tried and failed at least 1 non-steroidal antiinflammatory drug (NSAID), corticosteroid, OR sulfasalazine. 4. Plaque Psoriasis in patients that have: a) moderate to severe chronic disease, b) minimum body surface area (BSA) HUMIRA PEN-CROHNS DISEASESTARTER IMMUNE SUPPRESSANTS Documentation of diagnosis and past medication history. involvement of greater than or equal to 5% OR involvement of the palms, soles, head, neck or genitalia, c) tried and failed at least 1 topical agent (topical steroid, calcipotriene, or tazarotene), AND d) tried and failed at least 1 systemic therapy (cyclosporine, methotrexate, or acitretin) OR phototherapy. 5. Psoriatic Arthritis in patients with active disease. In addition, use of Humira or Remicade is considered medically necessary for the treatment of: 1. Moderate to severe Crohn s Disease in patients that have tried and failed at least 2 of the following: immunomodulators, corticosteroids, or aminosalicylates. 2. Treatment of moderately to severely active ulcerative colitis in patients who have had inadequate response to at least 2 of the following: corticosteroids, sulfasalazine, mesalamine, azathioprine, 6-mercaptopurine. Use of Remicade will also be considered medically necessary for the treatment of fistulizing Crohn's disease. B vs D determination required for Remicade. Use of Humira, Enbrel, or Remicade is considered medically necessary for the treatment of: 1. Rheumatoid Arthritis in patients that have tried and failed methotrexate OR at least 2 alternative disease modifying antirheumatic drugs (DMARDs). 2. Juvenile Rheumatoid Arthritis in patients that have tried and failed at least 2 DMARDs. 3. Ankylosing Spondylitis in patients that have tried and failed at least 1 non-steroidal antiinflammatory drug (NSAID), corticosteroid, OR sulfasalazine. 4. Plaque Psoriasis in patients that have: a) moderate to severe chronic disease, b) minimum body surface area (BSA) HUMIRA PEN- PEDIATRIC CROHNS DISEASESTARTER IMMUNE SUPPRESSANTS Documentation of diagnosis and past medication history. involvement of greater than or equal to 5% OR involvement of the palms, soles, head, neck or genitalia, c) tried and failed at least 1 topical agent (topical steroid, calcipotriene, or tazarotene), AND d) tried and failed at least 1 systemic therapy (cyclosporine, methotrexate, or acitretin) OR phototherapy. 5. Psoriatic Arthritis in patients with active disease. In addition, use of Humira or Remicade is considered medically necessary for the treatment of: 1. Moderate to severe Crohn s Disease in patients that have tried and failed at least 2 of the following: immunomodulators, corticosteroids, or aminosalicylates. 2. Treatment of moderately to severely active ulcerative colitis in patients who have had inadequate response to at least 2 of the following: corticosteroids, sulfasalazine, mesalamine, azathioprine, 6-mercaptopurine. Use of Remicade will also be considered medically necessary for the treatment of fistulizing Crohn's disease. B vs D determination required for Remicade.

19 Name Other Use of Humira, Enbrel, or Remicade is considered medically necessary for the treatment of: 1. Rheumatoid Arthritis in patients that have tried and failed methotrexate OR at least 2 alternative disease modifying antirheumatic drugs (DMARDs). 2. Juvenile Rheumatoid Arthritis in patients that have tried and failed at least 2 DMARDs. 3. Ankylosing Spondylitis in patients that have tried and failed at least 1 non-steroidal antiinflammatory drug (NSAID), corticosteroid, OR sulfasalazine. 4. Plaque Psoriasis in patients that have: a) moderate to severe chronic disease, b) minimum body surface area (BSA) involvement of greater than or equal to 5% OR involvement of the palms, soles, head, neck or genitalia, c) tried and failed at least 1 topical agent (topical steroid, calcipotriene, or tazarotene), AND d) tried and failed at least 1 systemic therapy (cyclosporine, methotrexate, or acitretin) OR phototherapy. 5. Psoriatic Arthritis in patients with active disease. In addition, use of Humira or Remicade is considered medically necessary for the treatment of: 1. Moderate to severe Crohn s Disease in patients that have tried and failed at least 2 of the following: immunomodulators, corticosteroids, or aminosalicylates. 2. Treatment of moderately to severely active ulcerative colitis in patients who have had inadequate response to at least 2 of the following: corticosteroids, sulfasalazine, mesalamine, azathioprine, 6-mercaptopurine. Use of Remicade will also be considered medically necessary for the treatment of fistulizing Crohn's disease. B vs D determination required for Remicade. HUMIRA PEN- PSORIASIS STARTER IMMUNE SUPPRESSANTS Documentation of diagnosis and past medication history. HYCAMTIN HYDROXYZINE HCL HRM - Hydroxyzine Oral For pruritus, safer alternatives are: Levocetirizine, Desloratadine. For anxiety, safer alternatives are: Buspirone, Fluoxetine, Paroxetine, Citalopram, and Venlafaxine. HYDROXYZINE HCL SOLUTION HRM - Hydroxyzine IM For anxiety, safer alternatives are: Buspirone, Fluoxetine, Paroxetine, Citalopram, and Venlafaxine. For nausea and vomiting, the safer alternative is ondansetron. HYDROXYZINE PAMOATE HRM - Hydroxyzine Oral For pruritus, safer alternatives are: Levocetirizine, Desloratadine. For anxiety, safer alternatives are: Buspirone, Fluoxetine, Paroxetine, Citalopram, and Venlafaxine. HYPERLYTE-CR IDAMYCIN PFS

20 Name Other IDARUBICIN HCL IFOSFAMIDE IFOSFAMIDE/MESNA ILARIS ILARIS BvsD Determination IMIPRAMINE HCL to New Starts HRM - Tricyclic Antidepressants Safer alternatives depend on indication. For Depression, safer alternatives are: Nortriptyline, Protriptyline, Desipramine, Amoxapine, Citalopram, Venlafaxine, Fluoxetine, Paroxetine, Sertraline, Duloxetine, and Bupropion. For headache prophylaxis, safer alternatives are: Propranolol, Topiramate, and Divalproex sodium. For headache treatment, safer alternatives are: Sumatriptan, Naratriptan, and Dihydroergotamine. For Pain/Neuropathy, safer alternatives are: Duloxetine, Lyrica, and Gabapentin. IMIPRAMINE PAMOATE to New Starts HRM - Tricyclic Antidepressants Safer alternatives depend on indication. For Depression, safer alternatives are: Nortriptyline, Protriptyline, Desipramine, Amoxapine, Citalopram, Venlafaxine, Fluoxetine, Paroxetine, Sertraline, Duloxetine, and Bupropion. For headache prophylaxis, safer alternatives are: Propranolol, Topiramate, and Divalproex sodium. For headache treatment, safer alternatives are: Sumatriptan, Naratriptan, and Dihydroergotamine. For Pain/Neuropathy, safer alternatives are: Duloxetine, Lyrica, and Gabapentin. INCIVEK INCRELEX INCIVEK INCRELEX Documentation from the medical record of diagnosis including genotype, current medication regimen, and HCV-RNA levels. Documentation of diagnosis. Documentation of lab data reflecting height standard deviation score, basal IGF-1 score, and growth hormone level. Prescribing physician must be an endocrinologist. 12 weeks Concurrent therapy with peginterferon alfa and ribavirin is required for Incivek. Height standard deviation score must be less than or equal to -3.0 AND the basal IGF-1 score must be below the lower limits of normal for the reporting lab AND the patient must have a normal or elevated growth hormone level (excluding patients with growth hormone gene deletion) AND epiphyses must be confirmed as open in patients greater than or equal to 10 years of age. INDOMETHACIN HRM - Indomethacin Safer alternatives are: Diclofenac, Diflunisal, Etodolac, Fenoprofen, Flurbiprofen, Ibuprofen, Ketoprofen, Nabumetone, Naproxen, Piroxicam, and Meloxicam.

21 Name Other INDOMETHACIN ER HRM - Indomethacin Safer alternatives are: Diclofenac, Diflunisal, Etodolac, Fenoprofen, Flurbiprofen, Ibuprofen, Ketoprofen, Nabumetone, Naproxen, Piroxicam, and Meloxicam. INFERGEN INFERGEN Documentation of genotype to determine length of therapy. 6 months INTRALIPID INVEGA TRINZA to New Starts INVEGA TRINZA excluded from Part D Documentation of diagnosis and past medication history Use of Invega Sustenna for a minimum of 4 months is required prior to use of Invega Trinza. IONOSOL- B/DEXTROSE 5% IONOSOL- MB/DEXTROSE 5% IPRATROPIUM BROMIDE IPRATROPIUM BROMIDE/ALBUTERO L SULFATE IRINOTECAN ISOLYTE-P/DEXTROSE 5% ISOLYTE-S ISTODAX IXEMPRA KIT JEVTANA KABIVEN KADCYLA

22 Name Other KALBITOR KALBITOR Kalbitor is authorized for the treatment of acute angioedema attacks with hereditary angioedema (HAE) when BOTH of the following criteria are met: 1) confirmed diagnosis of (HAE) as evidenced by a C4 level below the lower limit of normal as defined by the laboratory performing the test AND EITHER a) C1 inhibitor (C1INH) antigenic level below the lower limit of normal as defined by the laboratory performing the test or b) C1INH functional level below the lower limit of normal as defined by the laboratory performing the test AND 2) history of a moderate or severe attack (e.g., airway swelling, severe abdominal pain, facial swelling, nausea and vomiting, painful facial distortion). 16 years old and older KALYDECO KCL 0.075%/D5W/NACL 0.45% KALYDECO Patients with cystic fibrosis (CF) who are homozygous for the F508del mutation in the CFTR gene. CF mutation test documenting a G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, or S549R mutation in the CFTR gene. 6 years of age and older KCL 0.15%/D5W/LR KCL 0.15%/D5W/NACL 0.2% KCL 0.15%/D5W/NACL 0.225% KCL 0.15%/D5W/ NACL 0.3% KCL 0.15%/D5W/NACL 0.9% KCL 0.3%/D5W/NACL 0.45% KCL 0.3%/D5W/NACL 0.9% KCL 0.3%/D5W/LR IV LAC RING KEYTRUDA KORLYM LACTATED RINGERS DEXTROSE 5% VIAFLEX KORLYM

23 Name Other LANOXIN HRM - Digoxin the physician has documented that the patient has tried digoxin 0.125mg daily or provided clinical rationale as to why the lower dose is not LANOXIN PEDIATRIC HRM - Digoxin the physician has documented that the patient has tried digoxin 0.125mg daily or provided clinical rationale as to why the lower dose is not LAZANDA TRANSMUCOSAL FENTANYL CITRATE All FDA-approved Documentation from the medical record of diagnosis. 17 years of age and older for fentanyl citrate (lozenge/troche). 18 years of age and older for Lazanda. Enrollment in the Transmucosal Immediate- Release Fentanyl (TIRF) REMS Access program. Transmucosal fentanyl products will only be covered with documentation of breakthrough cancer pain. The patient must be currently receiving and be tolerant to opioid therapy for persistent cancer pain.the patient must be enrolled in the TIRF REMS Access program. LEUPROLIDE ACETATE to New Starts LEUPROLIDE ACETATE INJ For the treatment of prostate cancer, the patient must have failure, contraindication or intolerance to Trelstar before Lupron is authorized. BvsD Determination LEVALBUTEROL LEVALBUTEROL HCL LIDOCAINE LIDOCAINE PATCH For the FDA-labeled indication of postherpetic neuralgia, no additional criteria are required to be met. For OTHER types of offlabeled neuropathic pain: the patient must have previous use and inadequate response or intolerance to any ONE neuropathic pain medication, including (but not limited to) duloxetine and Lyrica that are labeled for neuropathic pain. LIPODOX LIPODOX 50 LIPOSYN II LIPOSYN III

24 Name Other LOPREEZA HRM - Estrogens Safer alternatives to the estrogen high risk medications depend on the indication. For Hot Flashes, safer alternatives are: Estradiol Valerate, Depo-Estradiol, SSRIs, venlafaxine, gabapentin, and Femring. For Vaginal Symptoms, safer alternatives are: Premarin Cream, Estring, Femring, and Estradiol Valerate. For Bone Density, safer alternatives are: alendronate, risedronate, Evista, and Prolia. LOTRONEX LUPRON DEPOT LUPRON DEPOT-PED LOTRONEX LEUPROLIDE ACETATE INJ LEUPROLIDE ACETATE INJ Lotronex (alosetron) will not be approved for use in men, as safety and efficacy in men has not been established. must be enrolled in the prescribing program for alosetron. For the treatment of prostate cancer, the patient must have failure, contraindication or intolerance to Trelstar before Lupron is authorized. BvsD Determination For the treatment of prostate cancer, the patient must have failure, contraindication or intolerance to Trelstar before Lupron is authorized. BvsD Determination MAGNESIUM SULFATE MAKENA MAKENA Makena is authorized to reduce the risk of preterm birth when ALL of the following are met: 1) current singleton pregnancy AND 2) previous singleton spontaneous preterm birth (preterm birth defined as birth from the period of viability through week 36, 6 days gestation) AND 3) treatment will be initiated between week 16, 0 days and week 20, 6 days of gestation and not continue beyond week 36, 6 days of gestation or time of delivery (whichever occurs first). up to 21 weeks BvsD Determination MARTEN-TAB HRM - Butalbital Combinations Safer alternatives are: naproxen sodium and ibuprofen. MEGACE ES HRM - Megestrol Suspension failed dronabinol or provided clinical rationale as to why that safer formulary alternative is not

25 Name Other MEGESTROL ACETATE SUSPENSION to New Starts HRM - Megestrol Suspension failed dronabinol or provided clinical rationale as to why that safer formulary alternative is not MEGESTROL ACETATE TABS to New Starts HRM - Megestrol Tabs documented the ongoing monitoring plan for the agent. age.prior Auth MELPHALAN HYDROCHLORIDE MENEST HRM - Menest failed one (1) safer formulary alternative or provided clinical rationale why the safer formulary alternative is not appropriate for the patient. For palliative therapy of metastatic breast cancer, no trial of a formulary alternative is required. age.prior Auth For vasomotor symptoms of menopause, safer alternatives are: SSRIs, venlafaxine, gabapentin, and Femring. For vaginal symptoms of menopause, safer alternatives are: Premarin Cream, Estring, and Femring. For all other indications, no formulary alternative is required. MENOSTAR HRM - Estrogens Safer alternatives to the estrogen high risk medications depend on the indication. For Hot Flashes, safer alternatives are: Estradiol Valerate, Depo-Estradiol, SSRIs, venlafaxine, gabapentin, and Femring. For Vaginal Symptoms, safer alternatives are: Premarin Cream, Estring, Femring, and Estradiol Valerate. For Bone Density, safer alternatives are: alendronate, risedronate, Evista, and Prolia. MESNA METHAMPHETAMINE HCL METHAMPHETAMINE HCL Patient must have failure, contraindication or intolerance to one formulary alternative such as dextroamphetamine, amphetamine/dextroamphetamine, methylphenidate or dexmethylphenidate before methamphetamine hcl is authorized.

26 Name Other MIMVEY HRM - Estrogens Safer alternatives to the estrogen high risk medications depend on the indication. For Hot Flashes, safer alternatives are: Estradiol Valerate, Depo-Estradiol, SSRIs, venlafaxine, gabapentin, and Femring. For Vaginal Symptoms, safer alternatives are: Premarin Cream, Estring, Femring, and Estradiol Valerate. For Bone Density, safer alternatives are: alendronate, risedronate, Evista, and Prolia. MITOMYCIN MITOXANTRONE HCL MODAFINIL MODAFINIL Documentation of diagnosis and sleep study for the diagnosis of sleep apnea or narcolepsy. For the treatment of narcolepsy, the patient must have failure, contraindication, or intolerance to methylphenidate or dextroamphetamine sulfate before modafinil is authorized. MUSTARGEN MYCOPHENOLATE MOFETIL MYCOPHENOLIC ACID DR MYFORTIC NAVELBINE NEBUPENT NEORAL NEPHRAMINE NEUMEGA NEUMEGA Documentation of diagnosis and lab data reflecting platelet count. Certified Hematologist and/or Oncologist up to 6 months Neumega is considered medically necessary for patients that have experienced severe thrombocytopenia (platelet count less than or equal to 20,000 mcg/l) from previous chemotherapy OR patients cosidered to be at high risk for the development of severe thrombocytopenia. BvsD Determination. NIPENT

27 Name Other NORDITROPIN FLEXPRO NORDITROPIN For GHD in children or adults, Turner Syndrome, SGA, SHOX gene deletion or growth delay in children with chronic kidney disease, the patient must have failure, contraindication or intolerance to Humatrope or Saizen before coverage of Norditropin. NORDITROPIN NORDIFLEX PEN NORDITROPIN For GHD in children or adults, Turner Syndrome, SGA, SHOX gene deletion or growth delay in children with chronic kidney disease, the patient must have failure, contraindication or intolerance to Humatrope or Saizen before coverage of Norditropin. NORETHINDRONE ACETATE/ETHINYL ESTRADIOL 2.5MCG; 0.5MG HRM - Estrogens Safer alternatives to the estrogen high risk medications depend on the indication. For Hot Flashes, safer alternatives are: Estradiol Valerate, Depo-Estradiol, SSRIs, venlafaxine, gabapentin, and Femring. For Vaginal Symptoms, safer alternatives are: Premarin Cream, Estring, Femring, and Estradiol Valerate. For Bone Density, safer alternatives are: alendronate, risedronate, Evista, and Prolia. NORMOSOL-M IN D5W NORMOSOL-R NORMOSOL-R IN D5W NULOJIX NUTRILIPID 20% IV FAT EMULSION NUTROPIN NUTROPIN For GHD in children or adults, Turner Syndrome, SGA or SHOX gene deletion, the patient must have failure, contraindication or intolerance to Humatrope or Saizen before coverage of Nutropin. NUTROPIN AQ NUSPIN 5 NUTROPIN For GHD in children or adults, Turner Syndrome, SGA or SHOX gene deletion, the patient must have failure, contraindication or intolerance to Humatrope or Saizen before coverage of Nutropin. NUTROPIN AQ PEN NUTROPIN For GHD in children or adults, Turner Syndrome, SGA or SHOX gene deletion, the patient must have failure, contraindication or intolerance to Humatrope or Saizen before coverage of Nutropin. NUVIGIL NUVIGIL Documentation of diagnosis and sleep study for the diagnosis of sleep apnea or narcolepsy. For the treatment of narcolepsy, the patient must have failure, contraindication, or intolerance to methylphenidate or dextroamphetamine sulfate before Nuvigil is authorized.

28 Name Other OCTAGAM OLYSIO OLYSIO Previous failure to respond to treatment with other HCV directacting protease inhibitors or Documentation from the medical record of diagnosis including repeated courses of simeprevir genotype, current medication regimen, and HCV-RNA levels. will result in exclusion of coverage for Olysio. 12 to 24 weeks based on indication and established treatment guidelines Concurrent therapy with peginterferon alfa and ribavirin is required for Olysio (unless Olysio is being used in combination with sofosbuvir). OMNITROPE OMNITROPE For GHD in children or adults, Turner Syndrome, SGA, SHOX gene deletion or growth delay in children with chronic kidney disease, the patient must have failure, contraindication or intolerance to Humatrope or Saizen before coverage of Omnitrope. ONCASPAR ONDANSETRON HCL ONDANSETRON ODT OPDIVO ORENCIA ORENCIA IV 6 years old and older Treatment of rheumatoid arthritis (RA) and when ANY of the following criteria are met: 1) history of positive clinical response to abatacept therapy OR 2) inadequate response, intolerance, or contraindication to at least one disease-modifying anti-rheumatic drug (DMARD) (i.e., Methotrexate (MTX) Azathioprine, gold, Hydroxychloroquine, Penicillamine, Sulfasalazine) AND when the following condition is met: the patient has had failure, contraindication, or intolerance to Enbrel or Humira. ORPHENADRINE CITRATE HRM - Skeletal Muscle Relaxants documented the ongoing monitoring plan for the agent. age.prior Auth ORPHENADRINE CITRATE ER HRM - Skeletal Muscle Relaxants documented the ongoing monitoring plan for the agent. age.prior Auth

29 Name Other OXALIPLATIN PACLITAXEL PAMIDRONATE DISODIUM PARICALCITOL PEG-INTRON PEG-INTRON REDIPEN PEG-INTRON PEG-INTRON Documentation of genotype to determine length of therapy. Documentation of genotype to determine length of therapy. 6 months 6 months PERFOROMIST PERIKABIVEN PERJETA PERPHENAZINE/AMIT RIPTYLINE to New Starts HRM - Perphenazine/Amitriptyli ne Safer alternatives are: Nortriptyline, Protriptyline, Desipramine, Amoxapine, Citalopram, Venlafaxine, Fluoxetine, Paroxetine, Sertraline, Duloxetine, and Bupropion. PHENADOZ HRM - Promethazine failed one (1) safer formulary alternative if available or provided clinical rationale why the safer formulary alternative is not age.prior Auth For nausea and vomiting, the safer alternative is ondansetron (QL = 90/30). For perennial and seasonal allergic rhinitis, safer alternatives are: levocetirizine and desloratadine. For any other indications, trial of a formulary alternative is not required. PHYSIOLYTE PHYSIOSOL IRRIGATION PLASMA-LYTE A PLASMA-LYTE-148

30 Name Other PLASMA-LYTE-56/D5W POTASSIUM CHLORIDE POTASSIUM CHLORIDE 0.15% /NACL 0.45% VIAFLEX POTASSIUM CHLORIDE 0.15% D5W/NACL 0.33% POTASSIUM CHLORIDE 0.15% D5W/NACL 0.45% POTASSIUM CHLORIDE 0.15%/NACL 0.9% POTASSIUM CHLORIDE 0.22% D5W/NACL 0.45% POTASSIUM CHLORIDE 0.3%/ NACL 0.9% POTASSIUM CHLORIDE 0.3%/D5W PREFEST HRM - Estrogens Safer alternatives to the estrogen high risk medications depend on the indication. For Hot Flashes, safer alternatives are: Estradiol Valerate, Depo-Estradiol, SSRIs, venlafaxine, gabapentin, and Femring. For Vaginal Symptoms, safer alternatives are: Premarin Cream, Estring, Femring, and Estradiol Valerate. For Bone Density, safer alternatives are: alendronate, risedronate, Evista, and Prolia. PREMARIN HRM - Estrogens Safer alternatives to the estrogen high risk medications depend on the indication. For Hot Flashes, safer alternatives are: Estradiol Valerate, Depo-Estradiol, SSRIs, venlafaxine, gabapentin, and Femring. For Vaginal Symptoms, safer alternatives are: Premarin Cream, Estring, Femring, and Estradiol Valerate. For Bone Density, safer alternatives are: alendronate, risedronate, Evista, and Prolia. PREMASOL

31 Name Other PREMPHASE HRM - Estrogens Safer alternatives to the estrogen high risk medications depend on the indication. For Hot Flashes, safer alternatives are: Estradiol Valerate, Depo-Estradiol, SSRIs, venlafaxine, gabapentin, and Femring. For Vaginal Symptoms, safer alternatives are: Premarin Cream, Estring, Femring, and Estradiol Valerate. For Bone Density, safer alternatives are: alendronate, risedronate, Evista, and Prolia. PREMPRO HRM - Estrogens Safer alternatives to the estrogen high risk medications depend on the indication. For Hot Flashes, safer alternatives are: Estradiol Valerate, Depo-Estradiol, SSRIs, venlafaxine, gabapentin, and Femring. For Vaginal Symptoms, safer alternatives are: Premarin Cream, Estring, Femring, and Estradiol Valerate. For Bone Density, safer alternatives are: alendronate, risedronate, Evista, and Prolia. PRIALT PRIVIGEN PROCALAMINE PROCRIT HEMATOPOIETICS For the indication of anemia, documentation of Hemoglobin less than 11, Hematocrit, transferrin saturation greater than 20%, and ferritin levels greater than 100 obtained over the last 3 months. 6 months BvD Determination. Patients must also have failure, contraindication or intolerance to Procrit or Aranesp before Epogen will be authorized. PROGRAF PROLASTIN-C Alpha-1 Proteinase Inhibitor Therapy All FDA-approved excluded from part D. Intravenous alpha1-proteinase inhibitor (human) is authorized for the treatment of congenital alpha1-proteinase inhibitor deficiency-associated lung disease when all of the following criteria are met: 1) alpha1-antitrypsin (AAT) concentration less than 80mg/dl or less than 11 micromolar and 2) obstructive lung disease as defined by a forced expiratory volume in one second (FEV1) of 30 to 65% of predicted or a rapid decline in lung function defined as a change in FEV1 of greater than 120ml per year. BvsD Determination. PROLEUKIN PROMETHAZINE HCL HRM - Promethazine failed one (1) safer formulary alternative if available or provided clinical rationale why the safer formulary alternative is not age.prior Auth For nausea and vomiting, the safer alternative is ondansetron (QL = 90/30). For perennial and seasonal allergic rhinitis, safer alternatives are: levocetirizine and desloratadine. For any other indications, trial of a formulary alternative is not required.

ACTEMRA. Cigna Medicare Rx (PDP) 2014 Cigna Medicare Rx Secure Plan (PDP) Formulary. Products Affected Actemra. Prior Authorization Criteria

ACTEMRA. Cigna Medicare Rx (PDP) 2014 Cigna Medicare Rx Secure Plan (PDP) Formulary. Products Affected Actemra. Prior Authorization Criteria Cigna Medicare Rx (PDP) Medicare Part D Prescription Drug Plans 2014 Cigna Medicare Rx Secure Plan (PDP) Formulary Prior Authorization ACTEMRA Products Affected Actemra PA Details Age Other Authorization

More information

2016 Cigna-HealthSpring Prior Authorization Criteria (Updated August 2016)

2016 Cigna-HealthSpring Prior Authorization Criteria (Updated August 2016) 2016 Cigna-HealthSpring Criteria (Updated August 2016) Drug Name Type Description Product Group Covered Uses Exclusion Criteria Required Medical Information Age Restrictions Prescriber Restrictions Coverage

More information

SASKATCHEWAN FORMULARY BULLETIN Update to the 62nd Edition of the Saskatchewan Formulary

SASKATCHEWAN FORMULARY BULLETIN Update to the 62nd Edition of the Saskatchewan Formulary November 1, 2014 Bulletin #150 ISSN 1923-0761 SASKATCHEWAN FORMULARY BULLETIN Update to the 62nd Edition of the Saskatchewan Formulary New Exception Drug Status (EDS) Listings Effective November 1, 2014

More information

Immune Modulating Drugs Prior Authorization Request Form

Immune Modulating Drugs Prior Authorization Request Form Patient: HPHC member ID #: Requesting provider: Phone: Servicing provider: Diagnosis: Contact for questions (name and phone #): Projected start and end date for requested Requesting provider NPI: Fax:

More information

Drugs covered under Medicare Part B or Part D

Drugs covered under Medicare Part B or Part D LABEL_NAME GENERIC_NAME MESSAGE GEMZAR INJ 1 GM GEMCITABINE HCL FOR INJ 1 GM ALIMTA INJ 500MG PEMETREXED DISODIUM FOR IV SOLN 500 MG (BASE EQUIV) FUNGIZONE INJ 50MG AMPHOTERICIN B FOR INJ 50 MG KYTRIL

More information

Remicade (infliximab)

Remicade (infliximab) Criteria for approval Commercial Only Remicade (infliximab) Background: Tumor Necrosis Factor (TNF) alpha is one of two proinflammatory cytokines that appear to play a dominant role in the inflammatory

More information

STAT Bulletin. Drug Therapy Guideline Updates. May 11, 2012 Volume: 18 Issue: 12

STAT Bulletin. Drug Therapy Guideline Updates. May 11, 2012 Volume: 18 Issue: 12 STAT Bulletin May 11, 2012 Volume: 18 Issue: 12 To: All primary care physicians and specialists Contracts Affected: All Lines of Business Drug Therapy Guideline Updates Why you re receiving this Stat What

More information

MEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES `I. Requirements for Prior Authorization of Cytokine and CAM Antagonists

MEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES `I. Requirements for Prior Authorization of Cytokine and CAM Antagonists MEDICAL ASSISTANCE HBOOK `I. Requirements for Prior Authorization of Cytokine and CAM Antagonists A. Prescriptions That Require Prior Authorization All prescriptions for Cytokine and CAM Antagonists must

More information

Prior Authorization FID 16157 VER.7 UPDATED 8/2015

Prior Authorization FID 16157 VER.7 UPDATED 8/2015 Prior Authorization FID 16157 VER.7 UPDATED 8/2015 Prior Authorization 2016 MAPD Leon 3 Tier Last Updated: 10/22/2015 ACTEMRA Products Affected Actemra INJ 162MG/0.9ML PA Details Other 1 ACTIMMUNE Products

More information

N/A N/A N/A. Supporting statement of diagnosis from the N/A. physician and documented trial of 1 generic. formulary alternative

N/A N/A N/A. Supporting statement of diagnosis from the N/A. physician and documented trial of 1 generic. formulary alternative Actimmune Amlodipine Androderm Anticonvulsant Antidepressants Antineoplastics Antipsychotics Arcalyst Butalbital Colony Stimulating Factors ESRD Therapy Actimmune Norvasc Androderm Banzel Keppra Mysoline

More information

Cytokine and CAM Antagonists

Cytokine and CAM Antagonists Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document Actemra (Tocilizumab) Drugs requiring prior authorization: the list of drugs

More information

Alameda Alliance for Health SPECIALTY PHARMACY PROGRAM FOR ALLIANCE MEDI-CAL AND GROUP CARE MEMBERS PROGRAM DESCRIPTION

Alameda Alliance for Health SPECIALTY PHARMACY PROGRAM FOR ALLIANCE MEDI-CAL AND GROUP CARE MEMBERS PROGRAM DESCRIPTION Alameda Alliance for Health SPECIALTY PHARMACY PROGRAM FOR ALLIANCE MEDI-CAL AND GROUP CARE MEMBERS PROGRAM DESCRIPTION Contents Page Program Overview 1 Process for Obtaining Authorization 2 Contacts 2

More information

Medications for chronic pain

Medications for chronic pain Medications for chronic pain When it comes to treating chronic pain with medications, there are many to choose from. Different types of pain medications are used for different pain conditions. You may

More information

Listing does not indicate formulary coverage. Please refer to membership materials to determine if medication is covered under your selected plan.

Listing does not indicate formulary coverage. Please refer to membership materials to determine if medication is covered under your selected plan. ACCUNEB Inhalation SOLN ACETYLCYSTEINE VIAL ALBUTEROL 0.083% INHAL SOLN ALBUTEROL 5 MG/ML ALBUTEROL SUL Inhalation SOL ANZEMET ATGAM 50 MG/ML AMPUL AZASAN AZATHIOPRINE VIAL AZATHIOPRINE BLEOMYCIN SULFATE

More information

subcutaneous initially every 4 weeks then every 12 weeks Coverage Criteria: Express Scripts, Inc. monograph dated 02/24/2010

subcutaneous initially every 4 weeks then every 12 weeks Coverage Criteria: Express Scripts, Inc. monograph dated 02/24/2010 BENEFIT DESCRIPTION AND LIMITATIONS OF COVERAGE ITEM: PRODUCT LINES: COVERED UNDER: DESCRIPTION: CPT/HCPCS Code: Company Supplying: Setting: Humira (adalimumab subcutaneous injection) Commercial HMO/PPO/CDHP

More information

ALZHEIMER'S DRUGS. Details. Step 2: Exelon Patch 13.3 mg/24 hour transdermal Exelon Patch 4.6 mg/24 hr transdermal

ALZHEIMER'S DRUGS. Details. Step 2: Exelon Patch 13.3 mg/24 hour transdermal Exelon Patch 4.6 mg/24 hr transdermal ALZHEIMER'S DRUGS Products Affected Step 1: donepezil 10 mg disintegrating tablet donepezil 10 mg tablet donepezil 23 mg tablet donepezil 5 mg disintegrating tablet donepezil 5 mg tablet galantamine 12

More information

Biologic Treatments for Rheumatoid Arthritis

Biologic Treatments for Rheumatoid Arthritis Biologic Treatments Rheumatoid Arthritis (also known as cytokine inhibitors, TNF inhibitors, IL 1 inhibitor, or Biologic Response Modifiers) Description Biologics are new class of drugs that have been

More information

Sovaldi (sofosbuvir) Prior Authorization Criteria

Sovaldi (sofosbuvir) Prior Authorization Criteria INITIAL REVIEW CRITERIA Sovaldi (sofosbuvir) Prior Authorization Criteria 1. Adult patient age 18 years old; AND 2. Prescribed by a hepatologist, gastroenterologist, infectious disease specialist, transplant

More information

DISEASE-MODIFYING ANTIRHEUMATIC DRUG THERAPY FOR RHEUMATOID ARTHRITIS

DISEASE-MODIFYING ANTIRHEUMATIC DRUG THERAPY FOR RHEUMATOID ARTHRITIS DISEASE-MODIFYING ANTIRHEUMATIC DRUG THERAPY FOR RHEUMATOID ARTHRITIS APPLICATIONS OBJECTIVE Purpose of Measure: ELIGIBLE POPULATION Which members are included? STANDARD OF CARE NCQA APPROVED CODES HEDIS

More information

SECTION 3. Criteria for Special Authorization of Select Drug Products. Section 3 Criteria for Special Authorization of Select Drug Products

SECTION 3. Criteria for Special Authorization of Select Drug Products. Section 3 Criteria for Special Authorization of Select Drug Products SECTION 3 Criteria for Special Authorization of Select Drug Products Section 3 Criteria for Special Authorization of Select Drug Products CRITERIA FOR SPECIAL AUTHORIZATION OF SELECT DRUG PRODUCTS The

More information

Original Policy Date

Original Policy Date MP 5.01.20 Tysabri (natalizumab) Medical Policy Section Prescription Drug Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Local Policy/12:2013 Return to Medical Policy Index Disclaimer

More information

Clinical Criteria for Hepatitis C (HCV) Therapy

Clinical Criteria for Hepatitis C (HCV) Therapy Diagnosis Clinical Criteria for Hepatitis C (HCV) Therapy Must have chronic hepatitis C, genotype and sub-genotype specified to determine the length of therapy; Liver biopsy or other accepted test demonstrating

More information

Hydration, IV Infusions, Injections and Vaccine Charge Process

Hydration, IV Infusions, Injections and Vaccine Charge Process There are a number of items to be considered when billing for the Nursing service to perform drug therapy, the charge process is divided into three specific groups of codes and processes. 1. Hydration

More information

Rheumatoid Arthritis. Outline. Treatment Goal 4/10/2013. Clinical evaluation New treatment options Future research Discussion

Rheumatoid Arthritis. Outline. Treatment Goal 4/10/2013. Clinical evaluation New treatment options Future research Discussion Rheumatoid Arthritis Robert L. Talbert, Pharm.D., FCCP, BCPS University of Texas at Austin College of Pharmacy University of Texas Health Science Center at San Antonio Outline Clinical evaluation New treatment

More information

MEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES I. Requirements for Prior Authorization of Tysabri

MEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES I. Requirements for Prior Authorization of Tysabri MEDICAL ASSISTANCE HBOOK PRI AUTHIZATION OF I. Requirements for Prior Authorization of Tysabri A. Prescriptions That Require Prior Authorization All prescriptions for Tysabri must be prior authorized.

More information

HEPATITIS C THERAPY PRIOR AUTHORIZATION FORM: Page 1 of 3 Patient Information. Diagnosis Acute Hep C Chronic Hep C Hepatocellular Carcinoma

HEPATITIS C THERAPY PRIOR AUTHORIZATION FORM: Page 1 of 3 Patient Information. Diagnosis Acute Hep C Chronic Hep C Hepatocellular Carcinoma HEPATITIS C THERAPY PRIOR AUTHORIZATION FORM: Page 1 of 3 Patient Information Recipient: MA#: Date of Birth: Phone #: Body Weight: Treatment Plan Sovaldi (sofosbuvir) 400mg: Take once daily for weeks Olysio

More information

Cytokine and CAM Antagonists

Cytokine and CAM Antagonists Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document Actemra (Tocilizumab) Drugs requiring prior authorization: the list of drugs

More information

North Carolina Rheumatology Association Position Statements

North Carolina Rheumatology Association Position Statements North Carolina Rheumatology Association Position Statements I. Biologic Agents A. Appropriate delivery, handling, storage and administration of biologic agents B. Indications for biologic agents II. III.

More information

MEDICATION GUIDE REMICADE (Rem-eh-kaid) (infliximab) Read the Medication Guide that comes with REMICADE before you receive the first treatment, and

MEDICATION GUIDE REMICADE (Rem-eh-kaid) (infliximab) Read the Medication Guide that comes with REMICADE before you receive the first treatment, and MEDICATION GUIDE REMICADE (Rem-eh-kaid) (infliximab) Read the Medication Guide that comes with REMICADE before you receive the first treatment, and before each time you get a treatment of REMICADE. This

More information

Prior Authorization Form

Prior Authorization Form Prior Authorization Form Growth Hormone This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign and date. Fax signed forms to CVS/Caremark at

More information

Evidence-based Management of Rheumatoid Arthritis (2009)

Evidence-based Management of Rheumatoid Arthritis (2009) CPLD reviews its distance learning programmes every twelve months to ensure currency. This update has been produced by an expert and should be read in conjunction with the Evidencebased Management of distance

More information

FEATURED GENERIC DRUG LIST

FEATURED GENERIC DRUG LIST FREE 30 DAY SUPPLY ON SELECT PRENATALS AND FLUORIDE SUPPLEMENTS Annual enrollment fee of $10 per family applies. SM *** -- A -- ACYCLOVIR 400 MG TABLET 60 180 ALBUTEROL SULFATE 2 MG/5 ML SYRUP 90 270 ALBUTEROL

More information

ACTEMRA. Step Therapy Criteria HEALTH CHOICE EXCHANGE 2016 Effective Date: 01/01/2016. PRODUCT(s) AFFECTED ACTEMRA

ACTEMRA. Step Therapy Criteria HEALTH CHOICE EXCHANGE 2016 Effective Date: 01/01/2016. PRODUCT(s) AFFECTED ACTEMRA ACTEMRA ACTEMRA Claim will pay automatically for Actemra if enrollee has a paid claim for at least a 1 days supply of Enbrel and Humira in the past 365 days. Otherwise, Actemra requires a step therapy

More information

MOH Policy for dispensing NEOPLASTIC DISEASES DRUGS

MOH Policy for dispensing NEOPLASTIC DISEASES DRUGS MOH Policy for dispensing NEOPLASTIC DISEASES DRUGS All prescriptions for antineoplastic drugs must be accompanied by the MOH special form. All the attachments mentioned on this form shall be submitted

More information

Arthritis and Rheumatology Clinics of Kansas Patient Education. Reactive Arthritis (ReA) / Inflammatory Bowel Disease (IBD) Arthritis

Arthritis and Rheumatology Clinics of Kansas Patient Education. Reactive Arthritis (ReA) / Inflammatory Bowel Disease (IBD) Arthritis Arthritis and Rheumatology Clinics of Kansas Patient Education Reactive Arthritis (ReA) / Inflammatory Bowel Disease (IBD) Arthritis Introduction: For as long as scientists have studied rheumatic disease,

More information

Co-pay assistance organizations offering assistance

Co-pay assistance organizations offering assistance Acromegaly Acute Exacerbations of Multiple Sclerosis Acute Porphyrias Advanced Idiopathic Parkinson' s Disease Age-Related Macular Degeneration www.theassistancefund.org Alcohol Dependence Alpha-1 Antitrypsin

More information

MEDICATION GUIDE. ACTEMRA (AC-TEM-RA) (tocilizumab) Solution for Intravenous Infusion

MEDICATION GUIDE. ACTEMRA (AC-TEM-RA) (tocilizumab) Solution for Intravenous Infusion MEDICATION GUIDE ACTEMRA (AC-TEM-RA) (tocilizumab) Solution for Intravenous Infusion ACTEMRA (AC-TEM-RA) (tocilizumab) Injection, Solution for Subcutaneous Administration Read this Medication Guide before

More information

2014 Valley Baptist Medicare D Formulary Step Therapy Criteria

2014 Valley Baptist Medicare D Formulary Step Therapy Criteria 2014 Valley Baptist Medicare D Formulary Step Therapy Products Affected ACTONEL TAB Last Updated 11/1/2014 Requires a trial of alendronate. 1 APLENZIN TAB Patient must have tried bupropion SR or bupropion

More information

Prior Authorization, Pharmacy and Health Case Management Information. Prior Authorization. Pharmacy Information. Health Case Management

Prior Authorization, Pharmacy and Health Case Management Information. Prior Authorization. Pharmacy Information. Health Case Management Prior Authorization, Pharmacy and Health Case Management Information The purpose of this information sheet is to provide you with details on how Great-West Life will be assessing and managing your claim

More information

PRIOR AUTHORIZATION PROTOCOL FOR HEPATITIS C TREATMENT

PRIOR AUTHORIZATION PROTOCOL FOR HEPATITIS C TREATMENT PRIOR AUTHORIZATION PROTOCOL FOR HEPATITIS C TREATMENT HARVONI (90mg ledipasvir/400mg sofosbuvir): tablet (PREFERRED AGENT) SOVALDI (sofosbuvir ): 400mg tablets (PREFERRED AGENT ) OLYSIO (simeprivir) PEG-INTRON

More information

Lupus in Children and Teenagers. Arielle Hay, MD Pediatric Rheumatologist Nicklaus Children s Hospital

Lupus in Children and Teenagers. Arielle Hay, MD Pediatric Rheumatologist Nicklaus Children s Hospital Lupus in Children and Teenagers Arielle Hay, MD Pediatric Rheumatologist Nicklaus Children s Hospital Systemic Lupus Erythematosus (SLE) Chronic Illness What is lupus? Autoimmune Multisystem Antinuclear

More information

PHARMACY PRIOR AUTHORIZATION

PHARMACY PRIOR AUTHORIZATION PHARMACY PRIOR AUTHORIZATION Hepatitis C Clinical Guideline Harvoni (sofosbuvir/ledipasvir), Sovaldi (sofosbuvir), Viekira PAK (ombitsavir, paritapravir/ritonavir, dasubavir), and Olysio (simeprevir) Authorization

More information

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Health Technology Appraisal

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Health Technology Appraisal NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Health Technology Appraisal Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure

More information

Arthritis in Children: Juvenile Rheumatoid Arthritis By Kerry V. Cooke

Arthritis in Children: Juvenile Rheumatoid Arthritis By Kerry V. Cooke Reading Comprehension Read the following essay on juvenile rheumatoid arthritis. Then use the information in the text to answer the questions that follow. Arthritis in Children: Juvenile Rheumatoid Arthritis

More information

2016 Prior Authorization Requirements

2016 Prior Authorization Requirements Group Health Medicare Advantage HMO 2016 PLEASE READ: Group Health requires you to get prior authorization for certain drugs. This means that you will need to get approval from Group Health before you

More information

Plan Year Allegian Advantage (HMO) Step Therapy Criteria (ST)

Plan Year Allegian Advantage (HMO) Step Therapy Criteria (ST) Plan Year 2015 Allegian Advantage (HMO) Step Therapy (ST) Step Therapy: In some cases, Allegian Advantage requires you to first try certain drugs to treat your medical condition before we will cover another

More information

Rheumatoid Arthritis

Rheumatoid Arthritis Rheumatoid Arthritis While rheumatoid arthritis (RA) has long been feared as one of the most disabling types of arthritis, the outlook has dramatically improved for many newly diagnosed patients. Certainly

More information

Drug Cost Estimates Generics

Drug Cost Estimates Generics Cost Estimates Generics Note: The retail pharmacy prices displayed below are estimates only. The actual price of your prescription W/ CODEINE TAB 300-30 MG ACYCLOVIR TAB 400 MG ALBUTEROL INHAL AEROSOL

More information

TREATMENT-RESISTANT DEPRESSION AND ANXIETY

TREATMENT-RESISTANT DEPRESSION AND ANXIETY University of Washington 2012 TREATMENT-RESISTANT DEPRESSION AND ANXIETY Catherine Howe, MD, PhD University of Washington School of Medicine Definition of treatment resistance Failure to remit after 2

More information

Page 1 of 5 Origination Date: 09/14 Revision Date(s): 10/2015, 02/2016, 07/2016 Developed By: Medical Criteria Committee 09/2014

Page 1 of 5 Origination Date: 09/14 Revision Date(s): 10/2015, 02/2016, 07/2016 Developed By: Medical Criteria Committee 09/2014 Moda Health Plan, Inc. Medical Necessity Criteria Subject: Stelara (ustekinumab) Page 1 of 5 Origination Date: 09/14 Revision Date(s): 10/2015, 02/2016, 07/2016 Developed By: Medical Criteria Committee

More information

NUVIGIL (armodafinil) oral tablet

NUVIGIL (armodafinil) oral tablet NUVIGIL (armodafinil) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy Coverage

More information

Preventing and Treating Nausea and Vomiting Caused by Cancer Treatment

Preventing and Treating Nausea and Vomiting Caused by Cancer Treatment A Patient s Guide Preventing and Treating Nausea and Vomiting Caused by Cancer Treatment Recommendations of the American Society of Clinical Oncology The American Society of Clinical Oncology (ASCO) is

More information

PRACTICAL HELP FROM THE ARTHRITIS FOUNDATION. www.arthritis.org 800-283-7800. Psoriatic Arthritis

PRACTICAL HELP FROM THE ARTHRITIS FOUNDATION. www.arthritis.org 800-283-7800. Psoriatic Arthritis Psoriatic Arthritis WHAT IS PSORIATIC ARTHRITIS? Psoriatic (sore-ee-aah-tick) arthritis is a condition that causes pain and swelling in joints and scaly patches on the skin. Psoriatic arthritis occurs

More information

NDC HCPCS HCPCS Description NDC Description Effective Date End Date X-Over Only

NDC HCPCS HCPCS Description NDC Description Effective Date End Date X-Over Only Updated 5.5.14 NDC HCPCS HCPCS Description NDC Description Effective Date End Date X-Over Only 68152-0103-03 A9543 YTTRIUM Y-90 IBRITUMOMAB TIUXETAN ZEVALIN Y-90 VIAL 9/1/2013 12/31/2013 50419-0320-05

More information

MEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. I. Requirements for Prior Authorization of Hepatitis C Agents

MEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. I. Requirements for Prior Authorization of Hepatitis C Agents MEDICAL ASSISTANCE HBOOK I. Requirements for Prior Authorization of Hepatitis C Agents A. Prescriptions That Require Prior Authorization Prescriptions for Hepatitis C Agents that meet any of the following

More information

Guideline for Management of Primary Headache in Adults

Guideline for Management of Primary Headache in Adults Guideline for Management of Primary Headache in Adults July 2012 This summary provides an evidence-based practical approach to assist primary health care providers in the diagnosis and management of adult

More information

Advanced Diagnostic Breast Cancer Imaging: Variation and Patterns of Care in Washington State

Advanced Diagnostic Breast Cancer Imaging: Variation and Patterns of Care in Washington State Advanced Diagnostic Breast Cancer Imaging: Variation and Patterns of Care in Washington State Gold, et al Supplemental Tables 1 3 Supplemental Table 1. Breast biopsy codes, types, and descriptions. Code

More information

Drug Therapy Guidelines: Humira (adalimumab)

Drug Therapy Guidelines: Humira (adalimumab) Drug Therapy Guidelines: Humira (adalimumab) Effective Date: 5/1/08 Committee Review Date: 1/6/01, 9/18/01, 1/15/02, 1/7/03, 1/20/04, 1/18/05, 12/7/05, 10/15/06, 7/2/07, 11/5/07, 3/25/08 Policy Statements:

More information

Rheumatoid Arthritis

Rheumatoid Arthritis What is Rheumatoid Arthritis? Rheumatoid Arthritis (RA) is a chronic and systemic disease that causes pain, stiffness, swelling, and limitation in the motion and function of multiple joints. Though joints

More information

SPECIAL AUTHORIZATION GUIDELINES

SPECIAL AUTHORIZATION GUIDELINES 91B ALBERTA DRUG BENEFIT LIST SPECIAL AUTHORIZATION GUIDELINES 37BSpecial Authorization Policy 90BDrug Products Eligible for Consideration by Special Authorization Drug Products may be considered for coverage

More information

MEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. I. Requirements for Prior Authorization of Hepatitis C Agents

MEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. I. Requirements for Prior Authorization of Hepatitis C Agents MEDICAL ASSISTANCE HBOOK PRI AUTHIZATION OF PHARMACEUTICAL SERVICES I. Requirements for Prior Authorization of Hepatitis C Agents A. Prescriptions That Require Prior Authorization Prescriptions for Interferon,

More information

Rheumatoid Arthritis Information

Rheumatoid Arthritis Information Rheumatoid Arthritis Information Definition Rheumatoid arthritis (RA) is a long-term disease that leads to inflammation of the joints and surrounding tissues. It can also affect other organs. Alternative

More information

for Extended Stability Parenteral Drugs Third Edition Caryn M. Bing, R.Ph., M.S., FASHP Editor

for Extended Stability Parenteral Drugs Third Edition Caryn M. Bing, R.Ph., M.S., FASHP Editor Extended Stability for Parenteral Drugs Third Edition Editor Caryn M. Bing, R.Ph., M.S., FASHP 1 American Society of Health-System Pharmacists Bethesda, Maryland Contents Preface Acknowledgments x/ Dedication

More information

Drugs Requiring Prior Authorization. Olysio. Subsys. Prolia. Tecfidera

Drugs Requiring Prior Authorization. Olysio. Subsys. Prolia. Tecfidera Abstral Acthar Hp Adcirca Adempas Affinitor Amitiza Amitriptyline Ampyra Androgel Androderm Androxy Aranesp Arcalyst Aubagio Avonex Bosulif Bydureon Byetta Cimzia Cinryze Clomipramine Cometriq Copaxone

More information

NEW DRUGS FOR THE TREATMENT OF HEPATITIS C. Marcella Honkonen, PharmD, BCPS AzPA Annual Convention. Sunday, June 29 th, 2014 (1:15-2:15)

NEW DRUGS FOR THE TREATMENT OF HEPATITIS C. Marcella Honkonen, PharmD, BCPS AzPA Annual Convention. Sunday, June 29 th, 2014 (1:15-2:15) NEW DRUGS FOR THE TREATMENT OF HEPATITIS C Marcella Honkonen, PharmD, BCPS AzPA Annual Convention. Sunday, June 29 th, 2014 (1:15-2:15) Objectives Determine initial treatment options for patients with

More information

J0207 INJECTION, AMIFOSTINE AMIFOSTINE 500 MG VIAL 3/1/ /99/9999

J0207 INJECTION, AMIFOSTINE AMIFOSTINE 500 MG VIAL 3/1/ /99/9999 50419 0320 05 A9581 INJECTION, GADOXETATE DISODIUM, 1 ML EOVIST 2.5 MMOL/10 ML VIAL 10/1/2011 99/99/9999 11994 0012 01 A9583 INJECTION, GADOFOSVESET TRISODIUM, 1 ML ABLAVAR 2.5 MMOL/10 ML VIAL 10/1/2011

More information

Migraine Diagnosis and Treatment

Migraine Diagnosis and Treatment Lehigh Valley Health Network LVHN Scholarly Works Neurology Update for the Non-Neurologist 2013 Neurology Update for the Non-Neurologist Feb 20th, 6:30 PM - 7:00 PM Migraine Diagnosis and Treatment Vitaliy

More information

Overview of Rheumatology

Overview of Rheumatology Overview of Rheumatology Griffin Hospital Mini Med School Stephen Moses, MD Valley Medical Associates 135 Division St. Ansonia, CT 06401 203.735.9354 Topics I. Anatomy of a Joint II. Osteoarthritis III.

More information

Drugs That Require Prior Authorization (PA) Before Being Approved for Coverage PRIOR AUTHORIZATION MEDICATIONS

Drugs That Require Prior Authorization (PA) Before Being Approved for Coverage PRIOR AUTHORIZATION MEDICATIONS That Require Prior Authorization (PA) Before Being Approved for Coverage PRIOR AUTHORIZATION MEDICATIONS ACNE Approve for those 12 years of age and older AVITA, RETIN-A MICRO, TRETINOIN ACTHAR HP All FDA-approved

More information

CLINICAL POLICY Department: Medical Management Document Name: Rheumatoid & Juvenile Arthritis and Ankylosing Spondylitis Treatments

CLINICAL POLICY Department: Medical Management Document Name: Rheumatoid & Juvenile Arthritis and Ankylosing Spondylitis Treatments Page: 1 of 18 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review and consideration of generally accepted

More information

Medicines for Psoriatic Arthritis. A Review of the Research for Adults

Medicines for Psoriatic Arthritis. A Review of the Research for Adults Medicines for Psoriatic Arthritis A Review of the Research for Adults Is This Information Right for Me? Yes, this information is right for you if: Your doctor* has told you that you have psoriatic (pronounced

More information

Growth Hormone Deficiency

Growth Hormone Deficiency Growth Hormone Deficiency What is growth hormone deficiency? 1,2 Growth hormone deficiency is when your body doesn t make enough growth hormone. Growth hormone is one of many hormones made by the pituitary

More information

Prior Authorization Requirements. Effective: 01/01/2016

Prior Authorization Requirements. Effective: 01/01/2016 Effective: 01/01/2016 Updated 11/2015 5HT3 ANTI-NAUSEA AGENT BVD DETERMINATION GRANISETRON HCL ONDANSETRON HCL ONDANSETRON ODT THIS DRUG MAY BE COVERED UNDER MEDICARE PART B OR D DEPENDING UPON THE CIRCUMSTANCES.

More information

Clinical Criteria for Hepatitis C (HCV) Therapy

Clinical Criteria for Hepatitis C (HCV) Therapy Diagnosis Clinical Criteria for Hepatitis C (HCV) Therapy Must have chronic hepatitis C (HCV infection > 6 months), genotype and sub-genotype specified to determine the length of therapy; Liver biopsy

More information

For renewals, patient must have responded to Actemra therapy (e.g., condition improved or stabilized).

For renewals, patient must have responded to Actemra therapy (e.g., condition improved or stabilized). PA Criteria ACTEMRA ACTEMRA Active infection (including TB). Concurrent therapy with other biologic agent(s). Screening for latent tuberculosis is required. If results are positive, patient must have completed

More information

Plan Year 2016. Vantage Health Plan (HMO) Prior Authorization (PA) Criteria

Plan Year 2016. Vantage Health Plan (HMO) Prior Authorization (PA) Criteria Plan Year 2016 Vantage Health Plan (HMO) Prior Authorization (PA) Criteria Prior Authorization: Vantage Health Plan requires you (or your physician) to get prior authorization for certain drugs. This means

More information

Medications most likely to be seen in primary care

Medications most likely to be seen in primary care Hazardous Medicines The majority of medicines are not classed as hazardous. The only medicinal products that are automatically deemed to be hazardous are cytotoxic and cytostatic medicines. There is no

More information

POST-TEST Pain Resource Professional Training Program University of Wisconsin Hospital & Clinics

POST-TEST Pain Resource Professional Training Program University of Wisconsin Hospital & Clinics POST-TEST University of Wisconsin Hospital & Clinics True/False/Don't Know - Circle the correct answer T F D 1. Changes in vital signs are reliable indicators of pain severity. T F D 2. Because of an underdeveloped

More information

Breast Cancer. Breast Cancer Page 1

Breast Cancer. Breast Cancer Page 1 Breast Cancer Summary Breast cancers which are detected early are curable by local treatments. The initial surgery will give the most information about the cancer; such as size or whether the glands (or

More information

RED Initiation and continuation in secondary care.

RED Initiation and continuation in secondary care. Guidance for safe transfer of prescribing Background information The majority of medicines prescribed to treat mental health illnesses are covered by NICE guidance. Where prescribing follows NICE recommendations

More information

Department of Vermont Health Access Pharmacy Benefit Management Program DUR Board Meeting Minutes: 03/11/2014

Department of Vermont Health Access Pharmacy Benefit Management Program DUR Board Meeting Minutes: 03/11/2014 Department of Vermont Health Access Pharmacy Benefit Management Program DUR Board Meeting Minutes: 03/11/2014 Board Members: Present: Joseph Lasek, MD, Chair Gary Starecheski, RPh Mark Pasanen, MD James

More information

PART III: CONSUMER INFORMATION

PART III: CONSUMER INFORMATION PART III: CONSUMER INFORMATION Pr REMICADE (Infliximab) This leaflet is part III of a three-part "Product Monograph" published when REMICADE was approved for sale in Canada and is designed specifically

More information

Medicines for Rheumatoid. Arthritis. A Review of the Research for Adults

Medicines for Rheumatoid. Arthritis. A Review of the Research for Adults Medicines for Rheumatoid Arthritis A Review of the Research for Adults Is This Information Right for Me? Yes, this summary is for you if: Your doctor* has told you that you have rheumatoid (pronounced

More information

Home Delivery Prescription Program Drug List

Home Delivery Prescription Program Drug List Home Delivery Prescription Program Drug List Low-cost prescriptions, right in your mailbox. Now you can have your generic prescriptions mailed right to your home, no matter where you live. Because we think

More information

Update on Hepatitis C. Sally Williams MD

Update on Hepatitis C. Sally Williams MD Update on Hepatitis C Sally Williams MD Hep C is Everywhere! Hepatitis C Magnitude of the Infection Probably 8 to 10 million people in the U.S. are infected with Hep C 30,000 new cases are diagnosed annually;

More information

Current Rheumatoid Arthritis Treatment Options: Update for Managed Care and Specialty Pharmacists

Current Rheumatoid Arthritis Treatment Options: Update for Managed Care and Specialty Pharmacists Current Rheumatoid Arthritis Treatment Options: Update for Managed Care and Specialty Pharmacists 1. Which of the following matches of biologic targets that contribute to rheumatoid arthritis (RA) and

More information

September 2014. Strategy or Medications Added or Modified Remove belladonna alkaloidsphenobarbital. Therapeutic Class/Drug Name.

September 2014. Strategy or Medications Added or Modified Remove belladonna alkaloidsphenobarbital. Therapeutic Class/Drug Name. The following changes to the Neighborhood formulary were recently approved by the Pharmacy and s (P&T) Committee. These changes are effective immediately unless otherwise indicated. Belladonna alkaloidsphenobarbital

More information

INITIATING ORAL AUBAGIO (teriflunomide) THERAPY

INITIATING ORAL AUBAGIO (teriflunomide) THERAPY FOR YOUR PATIENTS WITH RELAPSING FORMS OF MS INITIATING ORAL AUBAGIO (teriflunomide) THERAPY WARNING: HEPATOTOXICITY AND RISK OF TERATOGENICITY Severe liver injury including fatal liver failure has been

More information

How To Take Methotrexate By Injection

How To Take Methotrexate By Injection How To Take Methotrexate By Injection 1 how long does it take for methotrexate to work for abortion 2 methotrexate 15 mg hair loss 3 methotrexate injection dosage for rheumatoid arthritis 4 order methotrexate

More information

Prior Authorization Conditions for Approval of Hepatitis C Agents

Prior Authorization Conditions for Approval of Hepatitis C Agents Prior Authorization Conditions for Approval of Hepatitis C Agents All requests for Hepatitis C Agents require a prior authorization and will be screened for medical necessity and appropriateness using

More information

Medicare X- Overs Only

Medicare X- Overs Only 00703-5140-01 J0640 INJECTION, LEUCOVORIN CALCIUM, PER 50 MG LEUCOVORIN CALCIUM 100 MG V 03/01/2008 99/99/9999 00703-5145-01 J0640 INJECTION, LEUCOVORIN CALCIUM, PER 50 MG LEUCOVORIN CALCIUM 350 MG V 03/01/2008

More information

HealthPartners, Inc. 2013 Medicare Part D Formulary ID 13142, Version 22 Prior Authorization Criteria. Last Updated: 11/01/2013

HealthPartners, Inc. 2013 Medicare Part D Formulary ID 13142, Version 22 Prior Authorization Criteria. Last Updated: 11/01/2013 ACTEMRA Actemra (1) DIAGNOSIS OF MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS, OR (2) JUVENILE IDIOPATHIC ARTHRITIS, AND (3) DOCUMENTATION OF MEDICAL CONTRAINDICATIONS OR FAILURE WITH ENBREL OR HUMIRA.

More information

Psoriasis and Psoriatic Arthritis Alliance

Psoriasis and Psoriatic Arthritis Alliance Psoriasis and Psoriatic Arthritis Alliance A principal source of information on psoriasis and psoriatic arthritis ) Treatments for Psoriatic Arthritis overview Although psoriatic arthritis is a chronic

More information

to Part of Dossier: Name of Active Ingredient: Title of Study: Quality of life study with adalimumab in rheumatoid arthritis. ESCALAR.

to Part of Dossier: Name of Active Ingredient: Title of Study: Quality of life study with adalimumab in rheumatoid arthritis. ESCALAR. 2.0 Synopsis Abbott Laboratories Name of Study Drug: Individual Study Table Referring to Part of Dossier: Adalimumab (HUMIRA) (For National Authority Use Only) Name of Active Ingredient: Adalimumab Title

More information

FDA Approved Indications

FDA Approved Indications Preferred Agents: Humatrope (somatropin) Nutropin (somatropin) Medication Nutropin AQ (somatropin) Nutropin AQ NuSpin (somatropin) Non-Preferred Agents: Genotropin (somatropin) Omnitrope (somatropin) Norditropin

More information

Medications to Prevent and Treat Osteoporosis

Medications to Prevent and Treat Osteoporosis Medications to Prevent and Treat Osteoporosis National Institutes of Health Osteoporosis and Related Bone Diseases ~ National Resource Center 2 AMS Circle Bethesda, MD 20892-3676 Tel: (800) 624-BONE or

More information

Psoriatic arthritis FACTSHEET

Psoriatic arthritis FACTSHEET 1 What is psoriatic arthritis? Psoriatic arthritis (PsA) is a disease where joints around the body become inflamed and sore. It can make moving about difficult and painful. People who have PsA also have

More information

Efficacy and Tolerability of Antidepressant Duloxetine for Treatment of Hot Flushes in Menopausal Women

Efficacy and Tolerability of Antidepressant Duloxetine for Treatment of Hot Flushes in Menopausal Women Efficacy and Tolerability of Antidepressant Duloxetine for Treatment of Hot Flushes in Menopausal Women Irina Shestakova, MD, PhD Research Center of Obstetrics, Gynecology and Perinatology Department of

More information

Member Rights & Responsibilities

Member Rights & Responsibilities Member Rights & Responsibilities Member Rights and Responsibilities Blue KC has updated our Member Rights & Responsibilities to be consistent across all of our HMO and PPO products. Blue KC members have:

More information

Emergency and inpatient treatment of migraine: An American Headache Society

Emergency and inpatient treatment of migraine: An American Headache Society Emergency and inpatient treatment of migraine: An American Headache Society survey. The objective of this study was to determine the practice preferences of AHS members for acute migraine treatment in

More information